Form 4: Natera Executive Daniel Rabinowitz Executes Stock Options and Sells Shares

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., exercised stock options and sold shares of common stock on February 27 and 29, 2024, according to a Form 4 filing with the SEC.

Summary

• Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., reported transactions involving the company's common stock.
• On February 27, 2024, Rabinowitz exercised options to acquire 27,500 shares at $10.41 and 7,807 shares at $9.29.
• Also on February 27, 2024, Rabinowitz sold 35,307 shares at a weighted average price of $75.0927.
• On February 29, 2024, Rabinowitz exercised options to acquire 20,526 shares at $9.29.
• On February 29, 2024, Rabinowitz sold 100 shares at $85.1, 2,600 shares at a weighted average price of $86.6708, 3,400 shares at a weighted average price of $87.8721, and 14,426 shares at a weighted average price of $89.7235.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 13, 2022.
• Following these transactions, Rabinowitz directly owns 204,218 shares of Natera common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Executive stock sales are common across the biotechnology industry.
• The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.
• Comparable companies such as Exact Sciences (EXAS) and Guardant Health (GH) also see regular Form 4 filings from their executives.

Stakeholder Impact

• Shareholders may interpret the stock sales as a lack of confidence in the company's future performance, although the use of a pre-arranged trading plan mitigates this concern.
• The transactions have no direct impact on employees, customers, suppliers, or creditors.

Key Dates